<DOC>
	<DOCNO>NCT00582725</DOCNO>
	<brief_summary>Patients receive 6 8 cycle R-CHOP ( Rituximab , Cyclophosphamide , doxorubicin , vincristine , prednisone ) , GM-CSF .</brief_summary>
	<brief_title>R-CHOP + GM-CSF Previously Untreated LCL Elderly</brief_title>
	<detailed_description>The objective study estimate complete response rate patient treated regimen , assess overall response rate , event-free survival overall survival ; ass toxicity associate R-CHOP + GM-CSF . Patients receive 6 8 cycle R-CHOP ( Rituximab , Cyclophosphamide , doxorubicin , vincristine , prednisone ) , GM-CSF .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Histologically confirm , CD20+ B cell diffuse large cell lymphoma , measurable evaluable disease Having prior chemotherapy , immunotherapy radiotherapy except one cycle CHOP RCHOP . Pregnant Hepatitis B Surface Antigen positive Have know CNS disease HIV infection Have NY Classification III IV disease .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>DLBCL , Elderly</keyword>
	<keyword>previously untreated DLBCL elderly</keyword>
</DOC>